Nisa Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.1K Buy
2,637
+1,265
+92% +$4.89K ﹤0.01% 2310
2025
Q4
$5.61K Sell
1,372
-59,886
-98% -$297K ﹤0.01% 2429
2025
Q3
$299K Buy
61,258
+57,443
+1,506% +$302K ﹤0.01% 1160
2025
Q2
$19.3K Buy
3,815
+870
+30% +$4.27K ﹤0.01% 1957
2025
Q1
$15.6K Buy
2,945
+459
+18% +$3.35K ﹤0.01% 1980
2024
Q4
$16.8K Buy
2,486
+158
+7% +$1.06K ﹤0.01% 1990
2024
Q3
$15.3K Buy
2,328
+303
+15% +$2.17K ﹤0.01% 1988
2024
Q2
$15.2K Buy
2,025
+748
+59% +$6.52K ﹤0.01% 2036
2024
Q1
$12.7K Buy
1,277
+122
+11% +$1.36K ﹤0.01% 1996
2023
Q4
$11.4K Sell
1,155
-2,865
-71% -$20.4K ﹤0.01% 2015
2023
Q3
$30.8K Sell
4,020
-20
-0.5% -$200 ﹤0.01% 1876
2023
Q2
$30.2K Sell
4,040
-46,310
-92% -$324K ﹤0.01% 1936
2023
Q1
$336K Buy
50,350
+20
+0% +$159 ﹤0.01% 1180
2022
Q4
$388K Sell
50,330
-54
-0.1% -$530 ﹤0.01% 1191
2022
Q3
$536K Sell
50,384
-26,996
-35% -$273K ﹤0.01% 1007
2022
Q2
$630K Buy
77,380
+76,300
+7,065% +$511K 0.01% 974
2022
Q1
$8K Buy
+1,080
New +$11.5K ﹤0.01% 2246
2021
Q4
Sell
-2,777
Closed -$64 2309
2021
Q3
$64 Buy
+2,777
New +$78.7K ﹤0.01% 1868

Other funds holding RXRX

Nisa Investment Advisors's RXRX Position: Q1 2026 in Review

Nisa Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 92% in Q1 2026, buying an estimated $4.89K and bringing the position to 2,637 shares worth $8.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2310.

Nisa Investment Advisors first reported a position in RXRX in Q3 2021 and has held it in 18 quarters since. The position peaked at $630K in Q2 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Nisa Investment Advisors held 2,637 shares of Recursion Pharmaceuticals worth $8.1K as of Q1 2026.
  • Nisa Investment Advisors bought 1,265 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.89K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2310 holding.
  • Nisa Investment Advisors first reported a position in Recursion Pharmaceuticals in Q3 2021 and has held it in 18 quarters since.
  • Nisa Investment Advisors's Recursion Pharmaceuticals position peaked at $630K in Q2 2022.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.